LTK-14A

• Description :

  LTK-14A, a derivative of Garcinol (HY-107569), is a selective histone butyrylation inhibitor. LTK-14A does not affect acetylation. LTK-14A significantly inhibits the butyrylation of H4K5 and downregulated the expression of proadipogenic genes, thus culminating in abolished adipogenesis. LTK-14A can be used for the study of obesity[1].

• UNSPSC :

  12352005

• Target :

  HDAC

• Related Pathways :

  Cell Cycle/DNA Damage; Epigenetics

• Field of Research :

  Metabolic Disease

• Smiles :

  O=C([C@]1(C(C)2C)C/C=C(C)\C)[C@@](C[C@H]2C/C=C(C)/C)(C[C@@H]3C/C=C(C)\C)C(OC(C)3C)=C(C1=O)C(C(C=C4)=CC(OC)=C4OC)=O

• Molecular Formula :

  C40H54O6

• Molecular Weight :

  630.85

• References & Citations :

  [1]Bhattacharya A, et al. Butyrylation Meets Adipogenesis-Probed by a p300-Catalyzed Acylation-Specific Small Molecule Inhibitor: Implication in Anti-obesity Therapy. J Med Chem. 2022 Sep 22;65 (18) :12273-12291.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [71118-00-8]